Eris Lifesciences Limited has appointed Mr. Akhil Awasthi as an Additional Director (Non-executive, Independent). This appointment is for a term of five years, commencing September 26, 2026. Mr. Awasthi brings over three decades of experience in private equity, investment management, healthcare, and business transformation, with prior roles at Tata Capital Growth Fund and Baring Private Equity Partners.
Board Enhancement at Eris Lifesciences
Eris Lifesciences Limited announced today the appointment of Mr. Akhil Awasthi as an Additional Director to its Board. This appointment is designated as Non-executive and Independent, reinforcing the company’s commitment to robust corporate governance. The decision was approved by the Board of Directors following a recommendation from the Nomination and Remuneration Committee.
Strategic Appointment with Extensive Experience
Mr. Awasthi’s tenure as a director will commence on September 26, 2026, and will extend for a period of five years. His professional background spans over three decades, with significant expertise in private equity, investment management, and the healthcare and lifesciences sectors. He has held prominent positions, including Founding Managing Partner at Tata Capital Growth Fund and Partner at Baring Private Equity Partners (India) Ltd. His experience encompasses investments, strategic value creation, and board-level governance.
Director Independence and Compliance
Eris Lifesciences confirmed that Mr. Akhil Awasthi is not related to any existing directors on the Company’s Board. Furthermore, he is not debarred from holding a directorship by any regulatory authority, including SEBI. This appointment is subject to the approval of the company’s members.
Source: BSE
